Stakeholders must alter their mindsets when it comes to early-phase design and interpreting regulatory guidance for CGT trials.
Amy Raymond, PhD, PMP
Advertisement
Senior Director, Therapeutic Strategy Lead, Rare Disease, Worldwide Clinical Trials
Articles by Amy Raymond, PhD, PMP
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Nature Medicine Retracts Viral Lung Cancer Timing Study After Four-Month Investigation
2
Beyond Revenue Recognition: Rethinking CRO Contracting Through the CURED Shared Performance Contract
3
HHS Launches Operation TrialBlazer to Restore US Leadership in Clinical Research
4
Two Decades of Rising Protocol Complexity: A Longitudinal Analysis of Clinical Trial Design Evolution, 2004–2025
5